Ignite Creation Date:
2024-05-06 @ 2:13 AM
Last Modification Date:
2024-10-26 @ 11:15 AM
Study NCT ID:
NCT01990261
Status:
TERMINATED
Last Update Posted:
2016-09-16
First Post:
2013-10-31
Brief Title:
A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment
Sponsor:
Hoffmann-La Roche
Organization:
Hoffmann-La Roche
Study Overview
Official Title:
The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated Wild Type Patients Treated With Erlotinib TARceva After the Failure of at Least One Chemotherapy Regimen
Status:
TERMINATED
Status Verified Date:
2016-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STAR
Brief Summary:
This study will evaluate the survival of non-small cell lung cancer wild-type EGFR participants treated with Tarceva after at least one failed chemotherapy treatment and the impact of prior chemotherapy treatments
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None